Inhibition of Cysteine Proteases by 6,6'-Dihydroxythiobinupharidine (DTBN) from Nuphar lutea

Molecules. 2021 Aug 5;26(16):4743. doi: 10.3390/molecules26164743.

Abstract

The specificity of inhibition by 6,6'-dihydroxythiobinupharidine (DTBN) on cysteine proteases was demonstrated in this work. There were differences in the extent of inhibition, reflecting active site structural-steric and biochemical differences. Cathepsin S (IC50 = 3.2 μM) was most sensitive to inhibition by DTBN compared to Cathepsin B, L and papain (IC50 = 1359.4, 13.2 and 70.4 μM respectively). DTBN is inactive for the inhibition of Mpro of SARS-CoV-2. Docking simulations suggested a mechanism of interaction that was further supported by the biochemical results. In the docking results, it was shown that the cysteine sulphur of Cathepsin S, L and B was in close proximity to the DTBN thiaspirane ring, potentially forming the necessary conditions for a nucleophilic attack to form a disulfide bond. Covalent docking and molecular dynamic simulations were performed to validate disulfide bond formation and to determine the stability of Cathepsins-DTBN complexes, respectively. The lack of reactivity of DTBN against SARS-CoV-2 Mpro was attributed to a mismatch of the binding conformation of DTBN to the catalytic binding site of Mpro. Thus, gradations in reactivity among the tested Cathepsins may be conducive for a mechanism-based search for derivatives of nupharidine against COVID-19. This could be an alternative strategy to the large-scale screening of electrophilic inhibitors.

Keywords: 6,6′-dihydroxythiobinupharidine; Cathepsin; Mpro; Nuphar; SARS-CoV-2; covalent docking; cysteine proteases; molecular dynamic simulation.

MeSH terms

  • Alkaloids / chemistry
  • Alkaloids / pharmacology*
  • Animals
  • Antiviral Agents / pharmacology
  • Binding Sites
  • COVID-19 / metabolism
  • COVID-19 Drug Treatment
  • Catalytic Domain
  • Cathepsins / pharmacology
  • Cell Line, Tumor
  • Cysteine Proteases / chemistry
  • Cysteine Proteases / metabolism*
  • Cysteine Proteinase Inhibitors / chemistry
  • Cysteine Proteinase Inhibitors / pharmacology
  • Humans
  • Mice
  • Molecular Docking Simulation / methods
  • Nuphar / chemistry
  • Papain / pharmacology
  • Plant Extracts / pharmacology
  • Protein Binding
  • SARS-CoV-2 / drug effects

Substances

  • Alkaloids
  • Antiviral Agents
  • Cysteine Proteinase Inhibitors
  • Plant Extracts
  • dihydroxythiobinupharidine
  • Cathepsins
  • Cysteine Proteases
  • Papain